Failure is not an option for Africa’s newly launched medicines agency
Summary
The African Medicines Agency (AMA) has officially launched in Kigali after a decade of planning. The editorial argues that the AMA is a landmark development for health and science in Africa: a continent-wide regulator could raise standards for drugs and vaccines, improve local clinical trials, and support the continent’s push to manufacture more medical products domestically. The agency will draw on experience from the European Medicines Agency (EMA) but faces a very different landscape — most African countries import the majority of medicines and almost all vaccines, and only a handful of national regulators currently meet WHO maturity thresholds.
The AMA will need to prioritise training and capacity building, set standards for clinical-trial design, and foster research partnerships with universities, funders and industry. Initial donor funding of roughly €100 million covers early years, but sustainable local financing and rapid ratification by AU member states are critical for long-term success.
Key Points
- The AMA launched in Kigali and is hailed as a major step for African public health and science.
- It will borrow technical and regulatory know-how from the EMA but must adapt to Africa’s distinct needs.
- Only 9 of 55 AU member states currently have regulators meeting WHO quality thresholds to authorise clinical trials; this limits local approvals of medicines and vaccines.
- Improving clinical-trial capacity is essential: fewer than 3% of ~1.3 million global trials (1999–2024) took place in Africa.
- Initial funding (~€100 million from international donors) covers the first five years, but long-term sustainability requires AU states to increase financial support and complete treaty ratification.
- The AMA is central to Africa’s aim of on-continent vaccine and medicine manufacturing and to correcting pandemic-era inequities.
Context and relevance
The COVID-19 pandemic exposed deep inequities in vaccine access and highlighted the continent’s dependence on imports: Africa currently imports over 70% of medicines and about 99% of vaccines. A continent-level regulator can standardise regulatory frameworks, raise trial standards, and support domestic manufacturing — all of which feed into health security, economic development and scientific capacity building across Africa. The AMA’s success or failure will materially affect the feasibility of local production and the credibility of regulatory decisions across multiple countries.
Why should I read this?
Short version: this matters. If you care about global health, pharmaceutical policy, or African science and manufacturing, the AMA shapes whether future vaccines and medicines for African populations are tested, approved and produced closer to home. It’s the difference between waiting in line for imports and building local capability — so, yeah, give this one a read.
Author’s take
Punchy and to the point: the AMA is one of the most important public-health developments in Africa in years. It must deliver on training, funding and national buy-in — otherwise the continent risks repeating the same inequities seen during COVID‑19. This is a moment when momentum and political will need to turn into durable institutions.